Rimegepant - Fluorinated drugs for migraine with or without aura in adults

In February 2020, the U.S. Food and Drug Administration (FDA) approved three new molecular entity drugs (NME) for the treatment of migraine rimegepant, for the treatment of heterozygous familial hypercholesterolemia and atherosclerosis, for the single drug bempedoic acid, and for the compound drug bempedoic acid / ezetimide.

Among them, Rimegepant is a fluorine-containing drug, which is developed and marketed by biohaven, with the trade name of nurtec ODT. The structural formula is as follows：

Rimegepant is a CGRP receptor antagonist. In the histopathology of migraine, the activation of CGRP receptor is an important inducement. Intravenous injection of CGRP molecules can cause persistent pain in migraine patients and non migraine individuals. Therefore, the antagonists targeting CGRP and its receptor are important drug development directions. The target of rimegepant is calcrl (neuropeptide receptor like).

There are about 40 million migraine patients in the United States. Who classifies migraine as 10 general disability diseases. It can last for 4 to 72 hours. The common symptoms are throbbing headache with nausea and vomiting, which is sensitive to light and sound. Due to the serious interference of work and life, most patients need clinical emergency treatment intervention. Rimegepant will play its huge market potential.